A Clinicopathological Study of Malignant Insulinoma in a Contemporary Series Abstract #1257

Introduction: Malignant insulinoma is traditionally considered extremely rare and its natural history variable.
Aim(s): To summarize our institutional experience on malignant insulinoma in the last 15 years.
Materials and methods: Retrospective review of medical records and immunostaining of surgical specimen.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr. Run Yu

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1390 Ectopic Malignant Insulinoma with Multiple Liver Metastases: A Case Report
Introduction: Malignant insulinoma arising from ectopic pancreas is very rare.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr. Huang Ying Tan
Authors: Liu Q, Luo J, Li C, Zhu Z H, ...
#2124 A Case Report of a Malignant Insulinoma
Introduction: Despite rare (1-2% of pancreatic tumors/PT), insulinomas are the most common functional pNET. The diagnosis is established by demonstrating inappropriately high serum insulin levels during a spontaneous or induced episode of hypoglycemia.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Theodoros Tegos
Keywords: malignant, insulinoma
#2249 Pasireotide as a Possible Tool for the Control of Refractory Hyperinsulinemic Hypoglycemia from Malignant Insulinoma
Introduction: The control of hypoglycemic hyperinsulinemic syndrome from malignant insulinoma is challenging because it is often refractory to diazoxide and somatostatin analogues (SA). Everolimus can have side effects that can limit its use. Pasireotide, a multi-receptor-targeted SA with a high binding affinity to SSTR1 and SSTR5, exhibits a strong inhibitory effect of insulin secretion.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: MD Maria Vittoria Davì
#431 Everolimus Controlled Resistant Hypoglycemia in Malignant Insulinoma
Introduction: A pancreatic neuroendocrine carcinoma with liver metastases was diagnosed on July 2006 in a 65-year-old man. He was treated with octreotide LAR 30 mg for three years. At liver progression he was enrolled in a multicenter Italian trial titled “XELBEVOCT” with Bevacizumab + Metronomic Capecitabine + Octreotide LAR 30 mg. After seven months, the patient exhibited severe hypoglycemic syndrome with HGT serum levels<30 mg/dl, insulin 150 microUI/ml, and C-peptide at upper normal limits. Endocrinologist prescribed prednisone, diazoxide and recombinant glucagon for hypoglicemic crisis, with little benefit. In March 2010, the patient was given radio-labelled Lu-177-OCTREOTATE treatment. After three cycles, hypoglicemic symptoms were still uncontrolled. CT scan showed stable disease.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Anna Ferrero
Authors: Ferrero A, Bellini E, Brizzi M P, Pia A, ...
#2135 Is the Classification of Functioning-PanNET/Non-Functioning PanNET Properly? Insulinoma/Non-Insulinoma Is More Suitable to Distinguish the Clinicopathological and Prognosis Difference of Localized Insulinoma
Introduction: Pancreatic neuroendocrine tumor (PanNET) is classified into Functioning (F-PanNET) and Non-functioning (NF-PanNET) by hormone secretion. But insulinoma is slowly proliferating with unique features compared with Non-insulinoma F-PanNET (NiF-PanNET).
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Heli Gao
Authors: Gao H, Yu X, ...